




RealRate

PHARMACEUTICAL 2020

Unique N V
Rank 112 of 363

uniQure



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Unique N V are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unique N V compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Unique N V is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 66% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	384,206
Cost of Goods Sold	0
Intangible Assets	5,923
Liabilities, Current	31,630
Liabilities, Non-Current	93,942
Other Assets	29,730
Other Compr. Net Income	570
Other Expenses	5,838
Other Liabilities	0
Other Net Income	749
Other Revenues	9,169
Property and Equipment	28,771
Research and Development	94,737
Selling, General and Administrative Expense	33,544

Output Variable	Value in 1000 USD
Assets	448,630
Liabilities	125,572
Expenses	134,119
Revenues	9,169
Stockholders Equity	323,058
Net Income	-124,201
Comprehensive Net Income	-123,916
BaseVar	359,404
ECR before LimitedLiability	202%
Economic Capital Ratio	304%